Anti-inflammatory Drugs Market: By Indication (Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Psoriatic Arthritis, Gout)By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Biologics, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)), By Formulation (Oral, Parenteral, Topical) By Distribution Channel (Hospital Pharmacy, Clinics, Online Pharmacy, Retail Pharmacy) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Anti-inflammatory Drugs Market size was valued at USD 103.8 billion in 2022 and is poised to grow at a CAGR of 8.2% from 2023 - 2029. described by the nearness of driving players. The players in the market are to a great extent concentrating on the advancement of biologicals, which have less reactions and better adequacy. In spite of the fact that biologics are costly, their improved wellbeing and adequacy will enable sellers to get a bigger offer of the market once launched. The ascend in key partnerships by merchants is one of the most recent patterns that will pick up footing in the anti-inflammatory therapeutics market in the coming years. The anti-inflammatory therapeutics market is right now an expansion in the procurement of anti-inflammatory therapeutics by significant merchants. For example, one of the main player Pfizer as of late obtained Anacor Pharmaceuticals. This helped Pfizer pick up the business rights for Anacor Pharmaceuticals' crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, which was endorsed by the US FDA. Anti-inflammatory alludes to the property of a substance or treatment that diminishes irritation or swelling. The anti-inflammatory drugs Market make up about the portion of analgesics, curing torment by decreasing aggravation instead of opioids, which influence the focal sensory system to square torment motioning to the brain. Anti-inflammatory drugs are utilized to treat joint inflammation, sprains, excruciating periods and other difficult conditions. The vast majority experience no difficulty taking these tablets. In any case, a few people create symptoms which can now and again be not kidding. Specifically - on the off chance that you have any cardiovascular (heart, stroke, or vein) condition or certain gut conditions, or are elderly, these drugs are endorsed with alert and just where there are no choices and at the most minimal measurements and terms vital.

Anti Inflammatory Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Anti-inflammatory Drugs Market Dynamics

The worldwide anti-inflammatory market has been driven by variables, for example, expanding the immune system and respiratory diseases, new medications in pipeline and expanding the adoption of anti-inflammatory drugs. The interest for anti-inflammatory drugs has been expanding inferable from the rise of anti-inflammatory biologics that are more focused on, viable and with lesser symptoms when contrasted with traditional medications. Additionally, expanding familiarity with anti-inflammatory market therapeutics and alluring government activities in the Asia-Pacific and LAMEA area are relied upon to drive the market amid the investigation time frame. Factors such as symptoms of anti-inflammatory medications and patent expiry issues of blockbuster drugs, (for example, Remicade), are known to hinder the market development.

Anti Inflammatory Drugs Market Segmentation

By Application
  • Rheumatoid Arthritis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Multiple Sclerosis
  • Inflammatory Bowel Disease (IBD)
  • Psoriatic Arthritis
  • Gout
By Drug Class
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologics
  • Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
By Formulations
  • Oral
  • Parenteral
  • Topical
By End User
  • Hospital Pharmacy
  • Clinics
  • Online Pharmacy
  • Retail Pharmacy

Frequently Asked Questions

The anti-inflammatory drugs market size was valued at USD 103.8 billion in 2022

The anti-inflammatory drugs market key players are: Allergan, Inc. (S.) AbbVie Inc., (U.S.) Takeda Pharmaceutical Company Limited (Japan) Bayer AG (Switzerland) Pfizer Inc. (US) Reddys (India) Novartis (Switzerland) Sanofi Avemtis (France) Eli Lilly (US)

The anti-inflammatory drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Anti-inflammatory Drugs Market Introduction 
2.1.Global Anti-inflammatory Drugs Market  - Taxonomy
2.2.Global Anti-inflammatory Drugs Market  - Definitions
2.2.1.Application
2.2.2.Drug Class
2.2.3.Formulations
2.2.4.End User
2.2.5.Region
3. Global Anti-inflammatory Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Anti-inflammatory Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Anti-inflammatory Drugs Market  By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Rheumatoid Arthritis
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Chronic Obstructive Pulmonary Disease (COPD)
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Multiple Sclerosis
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Inflammatory Bowel Disease (IBD)
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Psoriatic Arthritis
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Gout
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6. Global Anti-inflammatory Drugs Market  By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Corticosteroids
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Biologics
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7. Global Anti-inflammatory Drugs Market  By Formulations, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parenteral
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Topical
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Anti-inflammatory Drugs Market  By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Hospital Pharmacy
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Clinics
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacy
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Retail Pharmacy
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.Global Anti-inflammatory Drugs Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Anti-inflammatory Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Rheumatoid Arthritis
10.1.2.Chronic Obstructive Pulmonary Disease (COPD)
10.1.3.Multiple Sclerosis
10.1.4.Inflammatory Bowel Disease (IBD)
10.1.5.Psoriatic Arthritis
10.1.6.Gout
10.2.  Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
10.2.2.Corticosteroids
10.2.3.Biologics
10.2.4.Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
10.3.  Formulations Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parenteral
10.3.3.Topical
10.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacy
10.4.2.Clinics
10.4.3.Online Pharmacy
10.4.4.Retail Pharmacy
10.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Anti-inflammatory Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Application Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Rheumatoid Arthritis
11.1.2.Chronic Obstructive Pulmonary Disease (COPD)
11.1.3.Multiple Sclerosis
11.1.4.Inflammatory Bowel Disease (IBD)
11.1.5.Psoriatic Arthritis
11.1.6.Gout
11.2.  Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
11.2.2.Corticosteroids
11.2.3.Biologics
11.2.4.Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
11.3.  Formulations Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parenteral
11.3.3.Topical
11.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacy
11.4.2.Clinics
11.4.3.Online Pharmacy
11.4.4.Retail Pharmacy
11.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Anti-inflammatory Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Application Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Rheumatoid Arthritis
12.1.2.Chronic Obstructive Pulmonary Disease (COPD)
12.1.3.Multiple Sclerosis
12.1.4.Inflammatory Bowel Disease (IBD)
12.1.5.Psoriatic Arthritis
12.1.6.Gout
12.2.  Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
12.2.2.Corticosteroids
12.2.3.Biologics
12.2.4.Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
12.3.  Formulations Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parenteral
12.3.3.Topical
12.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacy
12.4.2.Clinics
12.4.3.Online Pharmacy
12.4.4.Retail Pharmacy
12.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Anti-inflammatory Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Application Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Rheumatoid Arthritis
13.1.2.Chronic Obstructive Pulmonary Disease (COPD)
13.1.3.Multiple Sclerosis
13.1.4.Inflammatory Bowel Disease (IBD)
13.1.5.Psoriatic Arthritis
13.1.6.Gout
13.2.  Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
13.2.2.Corticosteroids
13.2.3.Biologics
13.2.4.Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
13.3.  Formulations Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parenteral
13.3.3.Topical
13.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacy
13.4.2.Clinics
13.4.3.Online Pharmacy
13.4.4.Retail Pharmacy
13.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14. Latin America Anti-inflammatory Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
14.1. Application Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Rheumatoid Arthritis
14.1.2.Chronic Obstructive Pulmonary Disease (COPD)
14.1.3.Multiple Sclerosis
14.1.4.Inflammatory Bowel Disease (IBD)
14.1.5.Psoriatic Arthritis
14.1.6.Gout
14.2.  Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
14.2.2.Corticosteroids
14.2.3.Biologics
14.2.4.Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)
14.3.  Formulations Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Parenteral
14.3.3.Topical
14.4.  End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacy
14.4.2.Clinics
14.4.3.Online Pharmacy
14.4.4.Retail Pharmacy
14.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Allergan, Inc. (S.)
15.2.2.AbbVie Inc., (U.S.)
15.2.3.Takeda Pharmaceutical Company Limited (Japan)
15.2.4.Bayer AG (Switzerland)
15.2.5.Pfizer Inc. (US)
15.2.6.Reddys (India)
15.2.7.Novartis (Switzerland)
15.2.8.Sanofi Avemtis (France)
15.2.9.Eli Lilly (US)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Allergan, Inc. (S.)
  • AbbVie Inc., (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Bayer AG (Switzerland)
  • Pfizer Inc. (US)
  • Reddys (India)
  • Novartis (Switzerland)
  • Sanofi Avemtis (France)
  • Eli Lilly (US)

Adjacent Markets